Long Shortz with Tryptamine Therapeutics: Fantastic fibromyalgia results off the back of US psychedelic trial
Stockhead TV
share
Stockhead’s Sarah Hughan sits down with Tryptamine Therapeutics’ (ASX:TYP) CEO Jason Carroll to get the short end of the long story on the company’s latest news.
The company undertook a Phase 2a trial with the University of Michigan, dosing fibromyalgia patients with its oral psilocybin formulation.
Fibromyalgia is associated with widespread pain and there are currently limited treatment options – 1M people in Australia and 10M people in the US currently suffer from it.
Tune in to hear Tryptamine Therapeutics’ Jason Carroll on the trial’s results, the company’s other IV-infused treatment, and more.
This video was developed in collaboration with Tryptamine Therapeutics, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
